NDA 020070 · Shionogi INC
Cognex
Tacrine Hydrochloride · Oral
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 19, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Sep 9, 1993
Approved uses
2
Original approval plus efficacy supplements
Registered trials
6
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 1997 Supplement 6 · Efficacy · priority review Review
- Sep 9, 1993 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
- COGNEX · TACRINE HYDROCHLORIDE EQ 30MG BASE · CAPSULE, ORAL · Discontinued
- COGNEX · TACRINE HYDROCHLORIDE EQ 10MG BASE · CAPSULE, ORAL · Discontinued
- COGNEX · TACRINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, ORAL · Discontinued
- COGNEX · TACRINE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tacrine" as an intervention, any sponsor and status, largest first.
- Chlorzoxazone in Hip and Knee ArthroplastyPivotal-lookingCompleted
Northern Orthopaedic Division, DenmarkAcademic, hospital or other
NCT02405104 · 400 participants · Start Sep 1, 2015 · Primary completion Dec 31, 2017
Drug: chlorzoxazone; Placebo · For: Osteoarthritis of Hip; Osteoarthritis, Knee
Sites: Farsø, Denmark
- Curcumin for Type 2 Diabetic PatientsPivotal-lookingStatus unknown
Srinakharinwirot UniversityAcademic, hospital or other
NCT01052597 · 200 participants (planned) · Start Jul 2009 · Primary completion Feb 2010
Drug: curcumin · For: Type 2 Diabetes Mellitus; Cardiovascular Abnormalities
Sites: Ongkarak, Thailand
- Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin ResistancePivotal-lookingStatus unknown
Srinakharinwirot UniversityAcademic, hospital or other
NCT01052025 · 200 participants (planned) · Start Aug 2009 · Primary completion Mar 2010
Drug: Curcumin · For: Type 2 Diabetes; Pre-diabetes; Insulin Resistance and 1 more
Sites: Ongkarak, Thailand
Lerdsin General HospitalAcademic, hospital or other
NCT00949351 · 80 participants (planned) · Start Sep 2009 · Primary completion Jul 2010
Drug: Aliskiren 300mg/d · For: Type 2 Diabetes With Nephropathy
Sites: Bangkok, Thailand
Yale UniversityAcademic, hospital or other
NCT00633256 · 20 participants · Start Dec 2006 · Primary completion Feb 2008
Drug: Cycloserine; Placebo · For: Smoking
Sites: West Haven, Connecticut
Midwest Biomedical ResearchAcademic, hospital or other
NCT01406522 · 0 participants · Start Oct 2012 · Primary completion Sep 2013
Drug: Oral tacrine; Oral placebo · For: Cocaine Dependence
Sites: Kansas City, Missouri
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cholinesterase inhibitors for delirium.
Overshott R, Karim S, Burns A · Cochrane Database Syst Rev 2008 · Systematic Review
- Tacrine for Alzheimer's disease.
Qizilbash N, Birks J, Lopez Arrieta J, et al. · Cochrane Database Syst Rev 2000 · Systematic Review
- Rivastigmine for Alzheimer's disease.
Birks J, Grimley Evans J, Iakovidou V, et al. · Cochrane Database Syst Rev 2000 · Systematic Review
- Rivastigmine for Alzheimer's disease.
Birks JS, Grimley Evans J · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Tacrine in Alzheimer's disease.
Eagger SA, Levy R, Sahakian BJ · Acta Neurol Scand Suppl 1992 · Clinical Trial, Randomized Controlled Trial
- Tacrine for Alzheimer's disease.
Qizilbash N, Birks J, López-Arrieta J, et al. · Cochrane Database Syst Rev 2000 · Systematic Review
Sponsor: Shionogi INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.